Bayer’s woes with compulsory licences


Mohan Dewan

Bayer’s woes with the Indian legal system are far from over. In 2011, the pharmaceutical company filed a suit to restrain India-based generic maker Natco from making, importing, selling or offering for sale cancer treatment drug sorafenib, sorafenib tosylate or any other generic version.

Mohan Dewan, R K Dewan & Co, India, Indian patent controller, Natco, patent, Bayer, Alembic Pharmaceuticals, section 107A, compulsory licence,